Literature DB >> 6418548

Fluvoxamine maleate: metabolism in man.

H Overmars, P M Scherpenisse, L C Post.   

Abstract

The metabolic fate of fluvoxamine maleate in man was investigated. The metabolites were isolated from the pooled urines of healthy volunteers who had ingested either 5 mg radioactive, or 100 mg non-radioactive fluvoxamine maleate as a single dose. The main isolation methods were solvent extraction, column and thin-layer chromatography. Eleven metabolites were isolated; eight of these were carboxylic acids. Identification of nine metabolites was accomplished by mass spectrometry supported by information from the UV spectra and the ionogenic properties. The main route of metabolic degradation of fluvoxamine begins with oxidative elimination of the methoxyl group, another route with removal of the primary amino group. In view of the nature of the degradation pattern none of the metabolites is likely to possess psychotropic activity. For the two primary metabolites this has, in effect, been demonstrated.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6418548     DOI: 10.1007/BF03188757

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  1 in total

1.  A new method for the separation of the catecholamines by gas-liquid chromatography.

Authors:  M G Horning; A M Moss; E C Horning
Journal:  Biochim Biophys Acta       Date:  1967-11-28
  1 in total
  16 in total

Review 1.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

Review 2.  Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.

Authors:  P Benfield; A Ward
Journal:  Drugs       Date:  1986-10       Impact factor: 9.546

3.  Excretion of fluvoxamine in breast milk.

Authors:  S Wright; S Dawling; J J Ashford
Journal:  Br J Clin Pharmacol       Date:  1991-02       Impact factor: 4.335

4.  Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients.

Authors:  Gisa Gerstenberg; Toshiaki Aoshima; Takashi Fukasawa; Keizo Yoshida; Hitoshi Takahashi; Hisashi Higuchi; Yoshiko Murata; Ritsuko Shimoyama; Tadashi Ohkubo; Tetsuo Shimizu; Koichi Otani
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

5.  Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs.

Authors:  Saeed Alqahtani; Amal Kaddoumi
Journal:  Clin Pharmacokinet       Date:  2016-08       Impact factor: 6.447

6.  Comparison of the effects of acute fluvoxamine and desipramine administration on melatonin and cortisol production in humans.

Authors:  D J Skene; C J Bojkowski; J Arendt
Journal:  Br J Clin Pharmacol       Date:  1994-02       Impact factor: 4.335

Review 7.  Treatment of anxiety and depression in transplant patients: pharmacokinetic considerations.

Authors:  Catherine C Crone; Geoffrey M Gabriel
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 8.  Overview of the pharmacokinetics of fluvoxamine.

Authors:  J van Harten
Journal:  Clin Pharmacokinet       Date:  1995       Impact factor: 6.447

Review 9.  Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.

Authors:  M I Wilde; G L Plosker; P Benfield
Journal:  Drugs       Date:  1993-11       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  J van Harten
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.